


Breakthrough/extension of thrombosis

Updated: 10/27/2017


1. [Potential causes of breakthrough](#)
2. [Anticoagulation management for confirmed breakthrough/extension](#)
3. [References](#)

Potential causes of breakthrough/extension



[Table of contents](#)

Anticoagulation management for confirmed breakthrough/extension



[Table of contents](#)

References

1. [Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016;149\(2\):315-52.](#)
2. [Crowl A, Schullo-feulner A, Moon JY. Warfarin monitoring in antiphospholipid syndrome and lupus anticoagulant. Ann Pharmacother. 2014;48\(11\):1479-83.](#)
3. [Carrier M, Lazo-langner A, Shivakumar S, et al. Screening for Occult Cancer in Unprovoked Venous Thromboembolism. N Engl J Med. 2015;373\(8\):697-704.](#)
4. [Schulman S. How I treat recurrent venous thromboembolism in patients receiving anticoagulant therapy. Blood. 2017;129\(25\):3285-3293.](#)
5. [Kyrle PA. How I treat recurrent deep-vein thrombosis. Blood. 2016;127\(6\):696-702.](#)
6. [Le gal G, Kovacs MJ, Carrier M, et al. Validation of a diagnostic approach to exclude recurrent venous thromboembolism. J Thromb Haemost. 2009;7\(5\):752-9.](#)
7. [Pengo V, Tripodi A, Reber G, et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2009;7\(10\):1737-40.](#)

[Return to last slide viewed](#)

[Table of Contents](#)